| Review of 1027 patients with newly diagnosed multiple myeloma RA Kyle, MA Gertz, TE Witzig, JA Lust, MQ Lacy, A Dispenzieri, ... Mayo clinic proceedings 78 (1), 21-33, 2003 | 3240 | 2003 |
| Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group International Myeloma Working Group British journal of haematology 121 (5), 749-757, 2003 | 2640 | 2003 |
| Initial genome sequencing and analysis of multiple myeloma MA Chapman, MS Lawrence, JJ Keats, K Cibulskis, C Sougnez, ... Nature 471 (7339), 467-472, 2011 | 1716 | 2011 |
| Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma JJ Keats, R Fonseca, M Chesi, R Schop, A Baker, WJ Chng, S Van Wier, ... Cancer cell 12 (2), 131-144, 2007 | 1228 | 2007 |
| POEMS syndrome: definitions and long-term outcome: Presented in abstract form at the 41st annual meeting of the American Society of Hematology, New Orleans, LA, December 3-7, 1999. A Dispenzieri, RA Kyle, MQ Lacy, SV Rajkumar, TM Therneau, DR Larson, ... Blood, The Journal of the American Society of Hematology 101 (7), 2496-2506, 2003 | 1219 | 2003 |
| Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised … SV Rajkumar, S Jacobus, NS Callander, R Fonseca, DH Vesole, ... The lancet oncology 11 (1), 29-37, 2010 | 1203 | 2010 |
| International Myeloma Working Group molecular classification of multiple myeloma: spotlight review R Fonseca, PL Bergsagel, J Drach, J Shaughnessy, N Gutierrez, ... Leukemia 23 (12), 2210-2221, 2009 | 1184 | 2009 |
| Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern … SV Rajkumar, E Blood, D Vesole, R Fonseca, PR Greipp Journal of clinical oncology 24 (3), 431-436, 2006 | 1134 | 2006 |
| Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy JG Lohr, P Stojanov, SL Carter, P Cruz-Gordillo, MS Lawrence, D Auclair, ... Cancer cell 25 (1), 91-101, 2014 | 1109 | 2014 |
| Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia RG Owen, SP Treon, A Al-Katib, R Fonseca, PR Greipp, ML McMaster, ... Seminars in oncology 30 (2), 110-115, 2003 | 1109 | 2003 |
| Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma RA Kyle, ED Remstein, TM Therneau, A Dispenzieri, PJ Kurtin, ... New England Journal of Medicine 356 (25), 2582-2590, 2007 | 1100 | 2007 |
| Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis A Dispenzieri, MA Gertz, RA Kyle, MQ Lacy, MF Burritt, TM Therneau, ... Journal of clinical oncology 22 (18), 3751-3757, 2004 | 1034 | 2004 |
| Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study SK Kumar, JH Lee, JJ Lahuerta, G Morgan, PG Richardson, J Crowley, ... Leukemia 26 (1), 149-157, 2012 | 957 | 2012 |
| Genetics and cytogenetics of multiple myeloma: a workshop report R Fonseca, B Barlogie, R Bataille, C Bastard, PL Bergsagel, M Chesi, ... Cancer research 64 (4), 1546-1558, 2004 | 939 | 2004 |
| Clinical and biologic implications of recurrent genomic aberrations in myeloma R Fonseca, E Blood, M Rue, D Harrington, MM Oken, RA Kyle, ... Blood 101 (11), 4569-4575, 2003 | 911 | 2003 |
| Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma SV Rajkumar, SR Hayman, MQ Lacy, A Dispenzieri, SM Geyer, B Kabat, ... Blood 106 (13), 4050-4053, 2005 | 873 | 2005 |
| Clonal competition with alternating dominance in multiple myeloma JJ Keats, M Chesi, JB Egan, VM Garbitt, SE Palmer, E Braggio, ... Blood, The Journal of the American Society of Hematology 120 (5), 1067-1076, 2012 | 782 | 2012 |
| Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma SV Rajkumar, S Hayman, MA Gertz, A Dispenzieri, MQ Lacy, PR Greipp, ... Journal of Clinical Oncology 20 (21), 4319-4323, 2002 | 703 | 2002 |
| Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide YX Zhu, E Braggio, CX Shi, LA Bruins, JE Schmidt, S Van Wier, XB Chang, ... Blood, The Journal of the American Society of Hematology 118 (18), 4771-4779, 2011 | 696 | 2011 |
| IMWG consensus on risk stratification in multiple myeloma WJ Chng, A Dispenzieri, CS Chim, R Fonseca, H Goldschmidt, ... Leukemia 28 (2), 269-277, 2014 | 694 | 2014 |
